Infliximab in refractory spondyloarthropathies: a multicentre 38 week open study

[...]the results of this open prospective trial clearly indicate that infliximab is an effective therapeutic option for patients with refractory SpA.

Saved in:
Bibliographic Details
Published in:Annals of the rheumatic diseases 2003-12, Vol.62 (12), p.1239-1240
Main Authors: Collantes-Estévez, E, Muñoz-Villanueva, M C, Cañete-Crespillo, J D, Sanmartí-Sala, R, Gratacós-Masmitjá, J, Zarco-Montejo, P, Torre-Alonso, J C, González-Fernández, C
Format: Article
Language:English
Subjects:
Adult
Antibodies, Monoclonal - therapeutic use
Antirheumatic Agents - therapeutic use
Bowel disease
Confidence intervals
Drug dosages
Drug Resistance
Female
Humans
Inflammation
Infliximab
Letter
Male
Patients
Prospective Studies
Spondylarthropathies - drug therapy
Thoracic Vertebrae
Working groups
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[...]the results of this open prospective trial clearly indicate that infliximab is an effective therapeutic option for patients with refractory SpA.
ISSN:0003-4967
1468-2060
DOI:10.1136/ard.2002.004879